EcoDrugPlus

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSDLEG00000013523
Gene Symbol: GLP2R
1 Cross references
205 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSDLEG00000003371
Gene Symbol: GCGR
1 Cross references
184 Possible Orthologues:

Glucokinase

Ensembl ID : ENSDLEG00000004482
Gene Symbol: GCK
3 Cross references
216 Possible Orthologues:

Glucosidase Alpha, Acid

Ensembl ID : ENSDLEG00000006032
Gene Symbol: GAA
3 Cross references
233 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSDLEG00000015111
Gene Symbol: GBA1
1 Cross references
256 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 1

Ensembl ID : ENSDLEG00000005310
Gene Symbol: GRIA1
3 Cross references
325 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSDLEG00000003472
Gene Symbol: GRIA2
3 Cross references
323 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 3

Ensembl ID : ENSDLEG00000017227
Gene Symbol: GRIA3
3 Cross references
249 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 4

Ensembl ID : ENSDLEG00000014352
Gene Symbol: GRIA4
3 Cross references
254 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 1

Ensembl ID : ENSDLEG00000014499
Gene Symbol: GRIN1
3 Cross references
275 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2a

Ensembl ID : ENSDLEG00000016261
Gene Symbol: GRIN2A
1 Cross references
295 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSDLEG00000001140
Gene Symbol: GRIN2B
3 Cross references
335 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).